A phase I trial of the oral hedgehog inhibitor taladegib (LY2940680) in combination with weekly paclitaxel in patients with advanced, solid tumours.
Rosalind Glasspool(Institut Bergonié), T.R. Jeffry Evans(Leiden University Medical Center), Trevor Tucker(Ignyta (United States)), James Paul(Cancer Research UK), Michelle Lockley(University College Hospital), Craig I. Campbell(University of Glasgow), Pratik S. Multani(Ignyta (United States)), Nivea' Douglas(Royal London Hospital), Chantévy Pou(University of Glasgow), Sarah P. Blagden(Churchill Hospital), Fiona Thomson(University of Glasgow), Iain A. McNeish(Imperial College London), Aishah Hanif(University of Glasgow), Ricardo A. Fernandes(Aarhus University), C. A. Hopkins(University of Glasgow), Jennifer R. Brown(Dana-Farber Cancer Institute)
Cited by 3
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k